問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

魏裕峰

Recruiting

List

39Cases

2022-05-10 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-03-01 - 2028-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-03-28 - 2026-08-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-11-29 - 2027-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-28 - 2022-12-31

Phase II

A Phase 2, open-label study of orally administered PAX-1 therapy in patients with brain metastases secondary to non-small cell lung cancer

  • Condition/Disease

    Brain metastases secondary to non-small cell lung cancer

  • Test Drug

    PAX-1

Participate Sites
8Sites

Recruiting8Sites

2020-05-01 - 2020-06-29

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer that Hasn’t Progressed After Prior Concurrent/Sequential Chemoradiotherapy.

  • Condition/Disease

    Non-Small Cell Lung Cancer Stage III

  • Test Drug

    CS1001

Participate Sites
6Sites

Recruiting6Sites

2016-11-01 - 2019-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2024-08-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2016-02-22 - 2022-12-22

Phase II

A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    INC280

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB